Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- AZ Initiates First Multinational PI Study under Agreement with NCC
January 23, 2013
- DSP Establishes Subsidiary in Singapore Eyeing Development of Business Operations for Latuda in Asia
January 23, 2013
- Kobayashi Kako, Elmed Eisai Set to Launch Allegra Generics on February 1
January 23, 2013
- Sanofi’s Dellegra Promotion to Home in on Stuffy Nose
January 22, 2013
- Santen Obtains Approval for Preservative-Free Ophthalmic Solution Tapros
January 22, 2013
- Kyorin and Daiichi Sankyo to Cancel Agreement on Uritos in Brazil
January 22, 2013
- Pfizer Detailing Infectious Disease Portfolios across Divisions
January 21, 2013
- Tokyo District Court to Issue Ruling on Actos Patent Suit on Feb. 27 after Takeda Lost Legal Battle in Osaka
January 21, 2013
- Drug Makers’ Specialty Care Pipelines Hit Snags in Late-Stage Development
January 21, 2013
- Daiichi Sankyo to Integrate Business Operations in Thailand with Ranbaxy
January 21, 2013
- Japan Could Get Left Behind in New Age of Open Innovation: Dr Fujimoto of Eli Lilly Japan
January 21, 2013
- Maruho to License Infantile Hemangioma Treatment from French Company
January 18, 2013
- Teijin Pharma Launches Acromegaly Treatment Somatuline
January 18, 2013
- Celgene K.K. Focused on MR Training Aiming for No. 1 Ranking Among Hematologists in 2013
January 18, 2013
- Ethical Drug Sales Up 2.4% in November: Crecon Report
January 18, 2013
- OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
- AZ K.K. President Hudson to Leave, Operations in Japan under Control of UK CFO
January 17, 2013
- Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
- Tivantinib Fails to Meet Primary Endpoint in PII Trial for Colorectal Cancer: Daiichi Sankyo
January 17, 2013
- Epadel Fails to Meet Endpoint in PII Trial with NASH Patients
January 16, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…